Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB3 (Ontruzant) vs Herceptin in HER2+ Early Breast Cancer
NCT02149524Phase 3Completed
- Sponsor
- Samsung Bioepis
- Start
- Apr 2014
- Primary completion
- Mar 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of trastuzumab-dttb in HER2-positive breast cancer (2 arms), sponsored by Samsung Bioepis. Primary endpoint: Pathologic Complete Response Rate of the Primary Breast Tumour at Week 24. Started Apr 2014; status: completed.
02
Drugs
trastuzumab-dttb
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT02149524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02149524.